Donepezil Viatris

Donepezil Viatris is a prescription oral tablet that contains the active ingredient donepezil hydrochloride, an acetylcholinesterase inhibitor used in the management of Alzheimer’s disease. Marketed in the European Union, the product follows the standard regulatory requirements for generic medicines and is supplied in tablet form for oral administration. It is classified under ATC code N06DA02 and is intended for use under medical supervision by healthcare professionals.

Donepezil Viatris is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease.

- Improves cognitive function such as memory, attention, and language. - Supports activities of daily living by enhancing neuronal communication. - May be used as part of a comprehensive care plan that includes non‑pharmacologic interventions. - Can be considered when a clinician determines that cholinergic augmentation is appropriate for a patient with diagnosed Alzheimer’s disease. - May be prescribed when other symptomatic treatments are insufficient or not tolerated. - Dosage adjustments may be considered based on renal function and patient response, following physician guidance.

The safety profile of Donepezil Viatris includes a range of adverse effects that have been reported in clinical use.

Common: - Nausea and vomiting, often occurring during the first weeks of treatment. - Diarrhea or loose stools, which may be mild to moderate. - Insomnia or vivid dreams, reflecting central cholinergic activity. - Muscle cramps, fatigue, or generalized weakness. - Decreased appetite leading to mild weight loss. - Dizziness or light‑headedness, particularly when standing.

Serious: - Bradycardia, heart block, or other clinically significant slowing of heart rate. - Severe gastrointestinal bleeding or ulceration. - Elevated liver enzymes indicating possible hepatotoxicity. - Seizures, especially in patients with a history of epilepsy. - Allergic reactions such as rash, pruritus, or angioedema.

When prescribing Donepezil Viatris, clinicians should consider several precautionary measures to ensure patient safety.

- Assess cardiac history, including bradyarrhythmias, before initiating therapy. - Review concomitant use of other cholinergic or anticholinergic agents. - Monitor liver function tests periodically during treatment. - Use caution in patients with severe renal impairment; dose adjustment may be required. - Evaluate for gastrointestinal disorders such as ulcer disease or reflux. - Consider the risk of falls in elderly patients due to dizziness. - Discuss potential pregnancy and lactation considerations, as safety data are limited.

Donepezil Viatris may interact with other medicines, influencing its efficacy or safety.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can increase donepezil plasma levels. - Anticholinergic drugs (e.g., diphenhydramine, atropine) that may reduce therapeutic effect.

Use with caution: - Beta‑blockers or other agents that lower heart rate, due to additive bradycardia risk. - NSAIDs or anticoagulants, which may raise the risk of gastrointestinal bleeding. - Other acetylcholinesterase inhibitors, as combined use can increase cholinergic side effects. - Drugs that affect hepatic metabolism (e.g., rifampin) potentially altering donepezil clearance. - Sedatives or hypnotics, as insomnia may be exacerbated.